Statewide framework for cancer care germline testing
The Statewide Cancer Clinical Network has identified the need for a statewide framework to standardise germline testing for cancer patients.
Read the full storyGermline testing provides important information to guide treatment decisions in cancer care. The use of germline testing in cancer care has expanded rapidly in recent years, partly due to the growth in knowledge and technology around genetic testing, including new treatment options available based on genetic testing results and an expansion in eligibility criteria for germline testing.
To support a streamlined and consistent pathway for patients accessing germline testing, the Cancer Statewide Clinical Network (CSCN) identified the need for a co-developed statewide framework. The development of the framework was guided by a multi-disciplinary working group, including representation from SA Pathology, Adelaide Genetics Unit (AGU), Local Health Networks (LHN) and consumers.
The working group, led by Dr Eryn Dow Clinical Cancer Geneticist from AGU, undertook consultation with relevant stakeholders across all SA LHNs which informed a comprehensive review of the current germline testing practice and pathways across LHNs.
To support the framework, mainstream genetic packs were developed and endorsed by the Cancer SCN. These packs are available on the Adult Genetics Unit AGU website for clinicians across the health system to support mainstream germline testing. The packs include information sheets, flowcharts, consent forms, testing criteria, guides, consent forms and partially filled pathology request forms. Education to support the framework and use of the packs was provided to cancer focussed multi-disciplinary team (MTD) meeting across LHNs.
Evaluation of the framework is underway, to measure effectiveness in terms of implementation, utility and outcomes. Consumer experience and satisfaction with the mainstreaming process will also be captured.
We would like to thank SA Pathology for their contribution toward the project to enable high level high level data oversight and enable the evaluation and monitoring of mainstreaming germline testing rates.